Background: Kounis syndrome is a hypersensitive coronary artery disease caused by the body's exposure to allergens, which is induced by various drugs and environmental factors. This entity has been described primarily in isolated case reports and case series. We report a case of type III Kounis syndrome caused by cefoperazone-sulbactam.
Case Presentation: A 79-year-old man who received an infusion of cefoperazone-sulbactam in Respiratory Department of our hospital for recurrent infections. 28 minutes later, he developed skin flushing of the trunk and extremities, soon followed by loss of consciousness and shock. With antianaphylaxis, pressor therapy, and fluid rehydration, the patient was admitted to the ICU for treatment. During which, he experienced recurrent ventricular fibrillation and a progressive increase in troponin I levels. The ECG of the patient showed that the ST segment elevation of lead II, III, avF, and V3R-V5R was 0.10-0.20 MV. An urgent coronary angiography showed an in-stent thrombosis in the middle part of the right coronary artery, occlusion of the distal flow with TIMI grade 0. The diagnosis was type III Kounis syndrome with cardiogenic shock. Despite aggressive treatment, the patient died on day 7 after ICU admission.
Conclusion: Kunis syndrome is a life-threatening disease, and therefore allergic reactions in patients with a history of cephalosporin allergy and coronary stent implantation should be considered and treated promptly.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709338 | PMC |
http://dx.doi.org/10.3389/fcvm.2022.1061586 | DOI Listing |
Eur J Case Rep Intern Med
December 2024
Emergency Department, Ente Ospedaliero Cantonale - Ospedale Regionale di Lugano, Lugano, Switzerland.
Unlabelled: Kounis syndrome (KS), characterized by the simultaneous occurrence of acute coronary syndrome (ACS) and allergic reactions, can be triggered by a range of factors and drugs. We report on the case of a patient who arrived at our emergency department (ED) with symptoms of an allergic reaction after taking moxifloxacin and deflazacort orally. In the ED, the patient experienced a 5-minute episode of oppressive chest pain.
View Article and Find Full Text PDFHum Vaccin Immunother
December 2024
Department of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
JACC Case Rep
November 2024
Interventional Cardiology, Careggi University Hospital, Florence, Italy.
J Investig Allergol Clin Immunol
November 2024
Department of Cardiology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
J Investig Allergol Clin Immunol
November 2024
Department of Allergy, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Hospital Universitario de La Princesa, Madrid, Spain.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!